Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News UCB says it committed to help CNS disease patients

UCB says it committed to help CNS disease patients

25th June 2009

UCB is committed to improving the lives of those who suffer from serious central nervous system (CNS) diseases, it has stated.

Along with Jazz Pharmaceuticals, the company has been analysing the potential of sodium oxybate (JZP-6) for the treatment of fibromyalgia.

Results from the second of two phase III clinical trials confirm the positive findings from the first investigation.

The medication significantly decreased fatigue and pain, as well as improved daily functions.

Chief medical officer at UCB Iris Loew-Friedrich explained the company is dedicated to helping people who suffer from such illnesses.

“The positive results of the two Phase III trials are encouraging and suggest that subject to regulatory approval, this may offer a new treatment option for people with fibromyalgia,” she said.

Lead investigator of the first study Dr I Jon Russell added sufferers of the chronic disease experience psychological distress and widespread pain, among other symptoms.

In May, the European Medicines Agency’s committee for medicinal products for human use granted UCB’s Neupro (rotigotine transdermal patch) a positive opinion for use in Europe.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.